The present invention provides a means for prevention and treatment of sarcopenia by administration of a substance that both reduces the sensibility of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propanol, tertalol, or bopindolol are preferred for this purpose.

Composicion farmacéutica de administracion oral que contiene ésteres alquílicos de ácidos grasos poliinsaturados (PUFA) y principios activos farmacéuticos betabloqueantes para el tratamiento y/o prevencion de enfermedades cardiovasculares. Reivindicacion 2: Composicion farmacéutica segun la reivindicacion 1 donde los ácidos grasos poliinsaturados de dichos ésteres alquílicos pertenecen a la serie omega-3. Reivindicacion 4: Composicion farmacéutica segun la reivindicacion 1 donde el radical alqui...

Pharmaceutical compsns. for transdermal systemic admin. of an active agent are claimed where (a) the active agent is bopindolol (I) or methysergide (II) or (b) the active agent is (I) (II) tizanidine (III) clemastine (IV) or ketotifen (V) in a reservoir comprising a hydrophilic polymer.

Dipeptides and amino acids of the formula A-E-G are disclosed wherein A is e.g. hydrogen or a- RbCO or RbSO2- where Ra and Rb are e.g. alkyl cycloalkyl or aryl;whereinR' is e.g. alkyl;n is 0 1;R2 is e.g. hydrogen or alkyl;R3 is OH NH2are e.g. alkyl;R4 is e.g. hydrogen or alkylR6 is H or methyl;R7 is e.g. hydrogen or alkyl;R8 is e.g. hydrogen methyl or cycloalkyl such that when R8 is cycloalkyl R6 and R7 are hydrogen;R9 is e.g. hydroxy.The compounds have enzyme inhibitor activity e.g. renin inhib...